Trial Profile
Effect of quadrivalent human papillomavirus vaccine on immune status of recurrent respiratory papillomatosis patients: An obsevational retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Mar 2017
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2017 Status changed from not stated to completed.
- 15 Mar 2017 New trial record